Lv5
1080 积分 2023-10-09 加入
Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria
9天前
已完结
Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice
10天前
已完结
Natural history of paroxysmal nocturnal hemoglobinuria
10天前
已完结
Consensus of the Hematology Society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH)
10天前
已关闭
Paroxysmal Nocturnal Hemoglobinuria
10天前
已完结
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial
18天前
已关闭
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
18天前
已完结
Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial
19天前
已关闭
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
19天前
已完结
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
19天前
已完结
皖公网安备34019202002308
